Cinqair
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.
TABLE OF CONTENTS
4 Product Profiles
4 Cinqair : Asthma
LIST OF FIGURES
9 Figure 54: Datamonitor Healthcare’s drug assessment summary of Xolair in asthma
10 Figure 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
13 Figure 3: Cinqair sales for asthma across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Cinqair drug profile
6 Table 2: Cinqair pivotal Phase III data in asthma
14 Table 3: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Flutiform 
Sign up to the